Ayça Gökçen Değirmenci Saltürk

Ayça Gökçen Değirmenci Saltürk

Auto-generated profile, based on publicly available information

Ayça Gökçen Değirmenci Saltürk

Univ Hlth Sci, Haydarpasa Numune Training & Res Hosp, Dept Gastroenterol, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2020 in Viral Hepatitis Journal
Verified
Journal Article
Closed access
ÖBÖzgür Bahadır
Özgür Bahadır
SÖSerhat Özer
Serhat Özer
ASAyça Gökçen Değirmenci Saltürk
Ayça Gökçen Değirmenci Saltürk
HŞHalil Şahin
Halil Şahin
MKMevlüt Kıyak
Mevlüt Kıyak
FGFatih Güzelbulut
Fatih Güzelbulut

1 January 2021 in Hepatology Forum
Verified
Journal Article
Closed access
PDF file
GAGupse Adali
Gupse Adali
PGPınar Gökçen
Pınar Gökçen
FGFatih Güzelbulut
Fatih Güzelbulut
ASAyça Gökçen Değirmenci Saltürk
Ayça Gökçen Değirmenci Saltürk
NANihat Bugra Agaoglu
Nihat Bugra Agaoglu
KÖKamil Özdil
Kamil Özdil
Background and Aims: The impact of chronic hepatitis B virus (HBV) infection and nucleos(t)ide analogs (NUCs) treatment on disease severity and clinical outcomes in patients 2 with COVID-19 is unknown. The aim was to determine whether HBV infection and the use of NUCs impact mortality in patients with COVID-19. Materials and Methods: We conducted a retrospective study of 231 adult patients (77 with COVID-19 and HBV coinfection) with a laboratory-confirmed diagnosis of COVID-19. Univariate and binary logistic regression analyses were performed to evaluate the risk factors for mortality from COVID-19. Results: Patients with COVID-19 and HBV coinfection had a similar rate of mortality as those without HBV coinfection (7.8% vs 9.7%, p=0.627). Cardiovascular disease (OR 8.22; 1.52-44.2, p=0.014) and high basal AST level (OR 7.94; 1.81-34.8, p=0.006) were independent predictors of mortality from COVID-19. In the COVID-19 and HBV coinfection group, patients who died had significantly higher median levels of HBV DNA than patients who survived (378 IU/mL vs 0 IU/mL, p=0.048). Thirty (39%) patients with HBV coinfection were receiving NUC treatment, and none of these patients died. Conclusion: HBV infection was not associated with mortality in patients with COVID-19, and NUCs for HBV infection might have an antiviral effect on SARS-CoV-2 infection.

1 January 2022 in Hepatology Forum
Verified
Journal Article
Open access
PDF file
OBOzgur Bahadır
Ozgur Bahadır
ASAyca Gokcen Degirmenci Salturk
Ayca Gokcen Degirmenci Salturk
MBMuzeyyen Arslan Bahadir
Muzeyyen Arslan Bahadir
Background and Aim: This study aimed to evaluate the changes in the clinical characteristics of chronic Hepatitis B (CHB) patients at the initiation of treatment over a 15-years period. Materials and Methods: The study included 659 treatment-naive CHB patients who started receiving nucleos(t)ide analogs between January 2006 and December 2020. The patients included in the study were divided into three groups of five years each, according to the start date of treatment. Results: The mean age was 46.2±14.5 years and 445 (67.5%) were male. Two hundred and five (31.1%) patients had cirrhosis. Hepatocellular carcinoma (HCC) developed in forty-one patients (6.2%). Compared to patients in Group 1, Group 2 were younger and had lower decompensated cirrhosis, HCC and ascites, had higher Child A cirrhosis (all p